A Mechanistic Tumor Penetration Model to Guide Antibody Drug Conjugate Design

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Vasalou, Christina ^b   Helmlinger, Gabriel ^c   Gomes, Bruce ^a  

^a Advanced Quantitative Sciences Novartis   (United States)

^b PFIZER INC   (United States)

^c Quantitative Clinical Pharmacology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY DRUG CONJUGATE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; BINDING SITE; BLOOD VESSEL PERMEABILITY; BYSTANDER EFFECT; CANCER CELL; CELL DEATH; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; ENDOCYTOSIS; INTERNALIZATION; MATHEMATICAL MODEL; MOUSE; NONHUMAN; RECEPTOR BINDING; TRANSPORT KINETICS; TUMOR XENOGRAFT; ANIMAL; BIOLOGICAL MODEL; CELL TRANSFORMATION; DRUG SCREENING; HUMAN; IMMUNOLOGY; KINETICS; METABOLISM; NEOPLASMS;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DRUG DESIGN; HUMANS; IMMUNOCONJUGATES; KINETICS; MICE; MODELS, BIOLOGICAL; NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84925436590     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0118977     Document Type: Article

References (50)

1. Burris HA, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, et al. Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer After Prior HER2-Directed Therapy. Journal of Clinical Oncology. 2011; 29(4):398-405. doi: 10.1200/JCO.2010.29.5865 PMID: 21172893
2. Krop I, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, et al. A Phase II Study of Trastuzumab- DM1 (T-DM1), a Novel HER2 Antibody-Drug Conjugate, in Patients Previously Treated with Lapatinib, Trastuzumab, and Chemotherapy. Cancer Research. 2009; 69(24):795S-S.
3. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results from a pivotal phase II study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL). ASCO Meeting Abstracts 2011. p. (15 suppl; abstr 8031).
4. www.clinicaltrial.gov.
5. Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003; 102(5):1578-82. PMID: 12738663
6. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Current Opinion in Chemical Biology. 2010; 14(4):529-37. doi: 10.1016/j.cbpa.2010.06.170 PMID: 20643572
7. Thurber GM, Weissleder R. A Systems Approach for Tumor Pharmacokinetics. Plos One. 2011; 6(9).
8. Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Molecular Cancer Therapeutics. 2009; 8(10):2861-71. doi: 10.1158/1535-7163.MCT-09-0195 PMID: 19825804
9. Shah DK, Betts AM. Antibody biodistribution coefficients Inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human. Mabs. 2013; 5(2):297-305. doi: 10.4161/mabs.23684 PMID: 23406896
10. Shah DK, Betts AM. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. Journal of Pharmacokinetics and Pharmacodynamics. 2012; 39(1):67-86. doi: 10.1007/s10928-011-9232-2 PMID: 22143261
11. Shah DK, Haddish-Berhane N, Betts A. Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin. Journal of Pharmacokinetics and Pharmacodynamics. 2012; 39(6):643-59. doi: 10.1007/s10928-012-9276-y PMID: 23151991
12. Jain RK, Baxter LT. MECHANISMS OF HETEROGENEOUS DISTRIBUTION OF MONOCLONAL-ANTIBODIES AND OTHER MACROMOLECULES IN TUMORS - SIGNIFICANCE OF ELEVATED INTERSTITIAL PRESSURE. Cancer Research. 1988; 48(24):7022-32. PMID: 3191477
13. Pluen A, Boucher Y, Ramanujan S, McKee TD, Gohongi T, di Tomaso E, et al. Role of tumor-host interactions in interstitial diffusion of macromolecules: Cranial vs. subcutaneous tumors. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98(8):4628-33. PMID: 11274375
14. Baxter LT, Jain RK. TRANSPORT OF FLUID AND MACROMOLECULES IN TUMORS. 4. A MICROSCOPIC MODEL OF THE PERIVASCULAR DISTRIBUTION. Microvascular Research. 1991; 41 (2):252-72. PMID: 2051960
15. Hendriks BS, Opresko LK, Wiley HS, Lauffenburger D. Coregulation of epidermal growth factor receptor/ human epidermal growth factor receptor 2 (HER2) levels and locations: Quantitative analysis of HER2 overexpression effects. Cancer Research. 2003; 63(5):1130-7. PMID: 12615732
16. Panetta JC. A mathematical model of breast and ovarian cancer treated with paclitaxel. Mathematical Biosciences. 1997; 146(2):89-113. PMID: 9348741
17. Thurber GM, Zajic SC, Wittrup KD. Theoretic criteria for antibody penetration into solid tumors and micrometastases. Journal of Nuclear Medicine. 2007; 48(6):995-9. PMID: 17504872
18. Lin YS, Nguyen C, Mendoza JL, Escandon E, Fei D, Meng YG, et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. Journal of Pharmacology and Experimental Therapeutics. 1999; 288(1):371-8. PMID: 9862791
19. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nature Biotechnology. 2005; 23(9):1126-36. PMID: 16151406
20. Less JR, Skalak TC, Sevick EM, Jain RK. MICROVASCULAR ARCHITECTURE IN A MAMMARYCARCINOMA- BRANCHING PATTERNS AND VESSEL DIMENSIONS. Cancer Research. 1991; 51 (1):265-73. PMID: 1988088
21. Less JR, Posner MC, Skalak TC, Wolmark N, Jain RK. Geometric resistance and microvascular network architecture of human colorectal carcinoma. Microcirculation-London. 1997; 4(1):25-33.
22. Porschen R, Classen S, Piontek M, Borchard F. VASCULARIZATION OF CARCINOMAS OF THE ESOPHAGUS AND ITS CORRELATION WITH TUMOR PROLIFERATION. Cancer Research. 1994; 54(2):587-91. PMID: 8275498
23. Hilmas DE, Gillette EL. MORPHOMETRIC ANALYSES OF MICROVASCULATURE OF TUMORS DURING GROWTH AND AFTER X-IRRADIATION. Cancer. 1974; 33(1):103-10. PMID: 4810083
24. Dellian M, Yuan F, Trubetskoy VS, Torchilin VP, Jain RK. Vascular permeability in a human tumour xenograft: molecular charge dependence. British Journal of Cancer. 2000; 82(9):1513-8. PMID: 10789717
25. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, et al. VASCULAR-PERMEABILITY IN A HUMAN TUMOR XENOGRAFT-MOLECULAR-SIZE DEPENDENCE AND CUTOFF SIZE. Cancer Research. 1995; 55(17):3752-6. PMID: 7641188
26. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Research. 2000; 60(9):2497-503. PMID: 10811131
27. Berk DA, Yuan F, Leunig M, Jain RK. Direct in vivo measurement of targeted binding in a human tumor xenograft. Proceedings of the National Academy of Sciences of the United States of America. 1997; 94 (5):1785-90. PMID: 9050856
28. Lauffenburger DA, LJ J. Receptors: Models for binding, Trafficking, and Signaling. Oxford University Press, Inc.; 1993. p. 30.
29. Felder S, Lavin J, Ullrich A, Schlessinger J. KINETICS OF BINDING, ENDOCYTOSIS, AND RECYCLING OF EGF RECEPTOR MUTANTS. Journal of Cell Biology. 1992; 117(1):203-12. PMID: 1556153
30. Fujimori K, Covell DG, Fletcher JE, Weinstein JN. MODELING ANALYSIS OF THE GLOBAL AND MICROSCOPIC DISTRIBUTION OF IMMUNOGLOBULIN-G, F(AB')2, AND FAB IN TUMORS. Cancer Research. 1989; 49(20):5656-63. PMID: 2790783
31. Wiig H, Gyenge CC, Tenstad O. The interstitial distribution of macromolecules in rat tumours is influenced by the negatively charged matrix components. Journal of Physiology-London. 2005; 567 (2):557-67. PMID: 15994186
32. Goh LK, Sorkin A. Endocytosis of Receptor Tyrosine Kinases. Cold Spring Harbor Perspectives in Biology. 2013; 5(5). doi: 10.1101/cshperspect.a017459 PMID: 23637288
33. Waters CM, Oberg KC, Carpenter G, Overholser KA. RATE CONSTANTS FOR BINDING, DISSOCIATION, AND INTERNALIZATION OF EGF-EFFECT OF RECEPTOR OCCUPANCY AND LIGAND CONCENTRATION. Biochemistry. 1990; 29(14):3563-9. PMID: 2354152
34. Okeley NM, Miyamoto JB, Zhang XQ, Sanderson RJ, Benjamin DR, Sievers EL, et al. Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate. Clinical Cancer Research. 2010; 16 (3):888-97. doi: 10.1158/1078-0432.CCR-09-2069 PMID: 20086002
35. Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Research. 2006; 66(8):4426-33. PMID: 16618769
36. Panetta JC, Schaiquevich P, Santana VM, Stewart CF. Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma. Clinical Cancer Research. 2008; 14(1):318-25. doi: 10.1158/1078-0432.CCR-07-1243 PMID: 18172284
37. Vona G, Sabile A, Louha M, Sitruk V, Romana S, Schutze K, et al. Isolation by size of epithelial tumor cells - A new method for the immunomorphological and molecular characterization of circulating tumor cells. American Journal of Pathology. 2000; 156(1):57-63. PMID: 10623654
38. Isobe T, Ikeda Y, Ohta H. COMPARISON OF SIZES AND SHAPES OF TUMOR-CELLS IN PLASMACELL LEUKEMIA AND PLASMA-CELL MYELOMA. Blood. 1979; 53(5):1028-30. PMID: 435639
39. Stoletov K, Montel V, Lester RD, Gonias SL, Klemke R. High-resolution imaging of the dynamic tumor cell-vascular interface in transparent zebrafish. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104(44):17406-11. PMID: 17954920
40. Mehrara E, Forssell-Aronsson E, Ahlman H, Bernhardt P. Specific growth rate versus doubling time for quantitative characterization of tumor growth rate. Cancer Research. 2007; 67(8):3970-5. PMID: 17440113
41. Juweid M, Neumann R, Paik C, Perezbacete MJ, Sato J, Vanosdol W, et al. MICROPHARMACOLOGY OF MONOCLONAL-ANTIBODIES IN SOLID TUMORS-DIRECT EXPERIMENTAL-EVIDENCE FOR A BINDING-SITE BARRIER. Cancer Research. 1992; 52(19):5144-53. PMID: 1327501
42. Ackerman ME, Pawlowski D, Wittrup KD. Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids. Molecular Cancer Therapeutics. 2008; 7(7):2233-40. doi: 10.1158/1535-7163.MCT-08-0067 PMID: 18645032
43. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, et al. High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Research. 2001; 61 (12):4750-5. PMID: 11406547
44. Rudnick SI, Lou JL, Shaller CC, Tang Y, Klein-Szanto AJP, Weiner LM, et al. Influence of Affinity and Antigen Internalization on the Uptake and Penetration of Anti-HER2 Antibodies in Solid Tumors. Cancer Research. 2011; 71(6):2250-9. doi: 10.1158/0008-5472.CAN-10-2277 PMID: 21406401
45. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nature Biotechnology. 2003; 21 (7):778-84. PMID: 12778055
46. Gerber HP, Koehn FE, Abraham RT. The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics. Natural Product Reports. 2013; 30(5):625-39. doi: 10.1039/ c3np20113a PMID: 23525375
47. Erickson HK, Widdison WC, Mayo MF, Whiteman K, Audette C, Wilhelm SD, et al. Tumor Delivery and In Vivo Processing of Disulfide-Linked and Thioether-Linked Antibody-Maytansinoid Conjugates. Bioconjugate Chemistry. 2010; 21(1):84-92. doi: 10.1021/bc900315y PMID: 19891424
48. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nature Reviews Drug Discovery. 2006; 5(3):219-34. PMID: 16518375
49. Kovtun YV, Audette CA, Ye YM, Xie HS, Ruberti MF, Phinney SJ, et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Research. 2006; 66(6):3214-21. PMID: 16540673
50. Hendriks BS, Wiley HS, Lauffenburger D. HER2-mediated effects on EGFR endosomal sorting: Analysis of biophysical mechanisms. Biophysical Journal. 2003; 85(4):2732-45. PMID: 14507736